Tracy Staton

Tracy Staton
Tracy Staton

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for 8 years. Before that, she served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont and can be reached at [email protected], or find her on LinkedIn.

Stories by Tracy Staton

For real R&D innovation, blur the lines between pharma and academia: Panel

Collaborating with academia has been de rigueur in the pharma world for years, but it's a different game these days. Recognizing that scientists on both sides of the divide can't be distant neighbors anymore, drugmakers and academics are invading each other's personal space, even working side-by-side in the same labs. They're learning unexpected things about their counterparts. And they're coming to terms with the inherent conflict between research for curiosity's sake and research for the market.

Pfizer and Allergan wend toward a $150B merger, reports say

Pfizer and Allergan are coming down to the wire on a merger that would be the biggest pharma deal ever. The all-stock transaction would be worth up to $150 billion, at a price of $370 to $380 per share, according to media reports, though analysts have estimated a per-share price of up to $400.

Is uniQure's gene therapy worth $1.4M?

The Federal Joint Committee is assessing uniQure's Glybera, the first-ever gene therapy approved in Europe, and now the world's most expensive drug at €1.1 million ($1.4 million). And the questions raised in Germany offer a preview of reimbursement conversations in other countries, about this and other uber-pricey gene therapies.